Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 1-18 (IGHV1-18) is a gene segment that encodes the variable region of the heavy chain of immunoglobulins (antibodies)[2][4]. The variable region is responsible for antigen binding and is generated through V(D)J recombination, which ensures the diversity of antibodies in the adaptive immune system[2][3]. This segment is part of the immunoglobulin heavy chain locus, which contains multiple variable, diversity, joining, and constant regions, with the variable regions determining the specificity for antigen recognition[1][3]. IGHV1-18 is therefore crucial for the adaptive immune response but does not act as a traditional therapeutic target (such as a receptor, enzyme, or transporter)[2][4]. Variation in IGHV genes contributes to the diversity of antibody responses and may indirectly influence susceptibility to immune-related diseases, but IGHV1-18 is not a direct disease driver or therapeutic receptor[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 1-18 (IGHV1-18).